Catalog No.
Product Name
Application
Product Information
Citations
-
STING Agonist
STING agonist-42 is a potent agonist of the stimulator of interferon genes (STING) pathway. It effectively activates STING in THP-1 and RAW 264.7 cells, demonstrating EC50 values of 0.06 μM and 14.15 μM, respectively. This compound can be utilized in research focused on immune modulation and the exploration of STING-related signaling pathways in various biological contexts. -
STING Agonist
C-di-IMP (Cyclic-di-IMP) is a small molecule that acts as a stimulator of the STING (Stimulator of Interferon Genes) pathway. It promotes immune activation and has significant implications in the study of cancer immunotherapy. This compound is valuable for research aimed at enhancing anti-tumor immunity and understanding the role of STING in modulating immune responses. -
STING Activator
STING agonist-11 (Compound 92) is a potent small molecule cyclic urea that selectively activates the stimulator of interferon genes (STING) pathway. With an EC50 of 18 nM, it enhances the immune response, making it a valuable tool in immunotherapy research. Its ability to modulate STING activity positions it for potential applications in cancer treatment and infectious disease models. -
STING Agonist
STING agonist-31 is a potent stimulator of the STING pathway, exhibiting EC50 values of 0.24 μM for human STING (h-STING) and 39.51 μM for mouse STING (m-STING). This compound demonstrates significant antitumor activity, making it an important tool for cancer research. It is suitable for studying the mechanisms of innate immunity and potential therapeutic applications in oncology. -
STING Agonist
STING Agonist-27 is a non-nucleotide small-molecule compound designed to activate the STING (Stimulator of Interferon Genes) pathway. This agonist showcases significant biological activity against various strains of SARS-CoV, making it valuable for research in antiviral mechanisms and immune modulation. Its application in studies targeting STING activation provides insights into therapeutic strategies for combating viral infections and enhancing innate immunity. -
STING Agonist
Antitumor agent-114 is a potent stimulator of interferon genes (STING) agonist. It effectively activates immune responses, leading to reduced tumor volume in preclinical mouse models of breast cancer. This compound is valuable for research in immunology and cancer therapy, contributing insights into immune modulation and tumor microenvironment interactions. -
PROTAC STING Degrader
PROTAC STING Degrader-2 is a targeted protein degrader that specifically induces the degradation of the Stimulator of Interferon Genes (STING) through a covalent interaction with STING and an E3 ubiquitin ligase. With a DC50 value of 0.53 μM, this compound facilitates the study of STING's biological functions, particularly in the context of autoinflammatory and autoimmune diseases. This reagent is instrumental for researchers exploring the therapeutic potential and role of STING in immune regulation. -
STING Inhibitor
STING-IN-14 is a potent STING inhibitor with an IC50 value of 0.6 nM. This compound effectively suppresses the activation of the IRF pathway in THP1-DualTM cells, making it a valuable tool for studying the role of STING in immune responses. STING-IN-14 is particularly relevant for research focused on autoimmune diseases, contributing to a better understanding of disease mechanisms and potential therapeutic interventions. -
STING Agonist
STING agonist-13 is an agonist of the stimulator of interferon genes (STING), promoting cancer immunity through STING-mediated immune activation. This compound effectively stimulates STING downstream signaling pathways, enhancing type I interferon responses. In preclinical studies, STING agonist-13 has demonstrated a significant reduction in tumor volume and the establishment of immunological memory, suggesting potential applications in cancer immunotherapy. -
STING Antagonist
STING antagonist-3 is a highly effective antagonist of the stimulator of interferon genes (STING) with an IC50 of 2.3 nM against human wild-type STING, as well as against the gain-of-function mutants N154S and V155M. This compound has been shown to inhibit the production of IFN-α2a in stimulated human whole blood and to reduce IP-10 levels in activated human dermal microvascular endothelial cells (HMVEC-d). STING antagonist-3 is valuable for research in autoimmune diseases, autoinflammatory diseases, interferonopathies, and fibrotic disorders. -
STING Agonist
diABZI-a1 is an orthosteric STING agonist that demonstrates an EC50 of 117 nM for the induction of IFNβ in human peripheral blood mononuclear cells (PBMCs). This compound is particularly relevant for research applications focused on monogenic autoinflammatory diseases, such as SAVI syndrome. Its ability to specifically activate the STING pathway makes diABZI-a1 a valuable tool for investigating immune responses and potential therapeutic interventions. -
STING Agonist
STING agonist-44 is a potent and selective agonist targeting the STING pathway. With an EC50 value of 5.68 µM for IRF induction in THP1 cells and 2.212 µM in RAW cells, this compound effectively stimulates the production of type I interferons and pro-inflammatory cytokines, such as CXCL10 and TNFα. STING agonist-44 is a valuable tool for research into cancer immunotherapy and related inflammatory conditions. -
STING Agonist
STING agonist-9 is a potent agonist of the STING (Stimulator of Interferon Genes) pathway, exhibiting an EC50 of 1.2 nM for human STING and 32.82 μM for mouse STING. This compound is known for its significant antitumor activity, making it a valuable tool for investigating immune responses in cancer research. STING agonist-9 is applicable in studies focused on immune activation and tumor microenvironment modulation. -
STING Modulator
STING modulator-5 is an inhibitor of the stimulator of interferon genes (STING) pathway, displaying a pIC50 value of 9.5. This compound effectively antagonizes peripheral blood mononuclear cells (PBMC) with a pIC50 of 8.1 and demonstrates activity against THP-1 cells. STING modulator-5 is a valuable tool for studying immunological diseases and exploring therapeutic avenues targeting STING-related signaling pathways. -
STING Inhibitor
STING modulator-3 is a selective STING inhibitor that targets the R232 variant of STING, exhibiting an inhibition constant (Ki) of 43.1 nM in scintillation proximity assays. This compound does not influence IRF-3 activation or TNF-β induction in THP-1 cells, making it a valuable tool for studying STING-mediated signaling pathways and their implications in immune responses and inflammatory diseases. Its specificity and potency provide researchers with a resource for exploring STING-related mechanisms in various biological contexts. -
STING Agonist
Parent CDN is a cyclic dinucleotide that acts as a Stimulator of Interferon Genes (STING) agonist. It has demonstrated significant anti-tumor activity by enhancing the innate immune response. This compound is utilized in research aimed at understanding immune modulation and cancer immunotherapy. -
STING Agonist
SAP-04 is a potent STING agonist that activates the stimulator of interferon genes pathway, enhancing innate immune responses. This compound demonstrates significant immunomodulatory effects, making it a valuable tool in cancer therapy research. Its oral bioactivity provides convenience for in vivo studies, facilitating the exploration of immune-mediated mechanisms in tumor immunology. -
STING Agonist
(S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide is a potent STING (stimulator of interferon genes) agonist. It exhibits a significant inhibitory effect on 3H-cGAMP binding to STING, with an IC50 value of 14 μM. This compound is valuable for research applications in tumor biology and immune response modulation, particularly in the context of cancer immunotherapy. -
hSTING Modulator
Clonixeril (NSC 335504) is a non-nucleotide modulator of human STING (hSTING), exhibiting a unique dual mechanism of action. It acts as a weak agonist at micromolar concentrations while demonstrating antagonistic properties of the hSTINGWT pathway at low femtomolar and attomolar levels. Clonixeril effectively reduces hSTING oligomerization, proving useful in elucidating the complexities of STING signaling and its role in immune responses. This compound serves as a valuable tool for research in immunology and drug discovery targeting STING-related pathways. -
STING Agonist
STING agonist-29 is a small-molecule agonist targeting the stimulator of interferon genes (STING). This compound demonstrates the ability to activate the STING pathway, leading to the induction of type I interferons and pro-inflammatory cytokines. It is particularly notable for its antiviral activity against SARS-CoV strains, making it a valuable tool for research focused on innate immunity and viral infection responses. -
STING Agonist
STING Agonist-43 is a selective STING (Stimulator of Interferon Genes) agonist that activates the cGAMP-dependent STING signaling pathway, with an EC50 of 20.53 μM. This compound enhances STING oligomerization, leading to increased activation and subsequent immune response. In preclinical studies, STING agonist-43 demonstrated antitumor efficacy in a mouse melanoma model, making it a valuable tool for investigating cancer immunity and the potential for immunotherapeutic strategies. -
STING Agonist
STING agonist-34 is a potent stimulator of the STING pathway, exhibiting an IC50 value of 1.15 μM and an EC50 value of 0.38 μM in THP1 cells. This compound activates the cGAS-STING signaling pathway, promoting type I interferon production and enhancing immune responses. STING agonist-34 is applicable in cancer research and immunotherapy studies, offering potential insights into tumor microenvironments and therapeutic strategies against malignancies. -
STING Agonist
STING agonist-25 (CF505) is a non-nucleotide small-molecule activator of the Stimulator of Interferon Genes (STING). This compound enhances the phosphorylation of STING, TBK1, and IRF3, leading to elevated levels of pro-inflammatory cytokines such as IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-25 shows potential in antiviral research, particularly against strains of SARS-CoV. -
STING Activator
STING agonist-10 is a potent small molecule cyclic urea that activates the Stimulator of Interferon Genes (STING) pathway, with an EC50 of 2600 nM. This compound enhances the immune response by stimulating the production of type I interferons, making it a valuable tool in immunotherapy research. Its ability to modulate STING activity holds potential for applications in the treatment of various cancers and infectious diseases. -
STING Agonist
BSP16 is a potent agonist of stimulator of interferon genes (STING), functioning through selective activation of the STING pathway. It exhibits significant biological activity in promoting immune responses, making it a valuable tool for cancer research and immunotherapy studies. BSP16 enables researchers to explore the therapeutic potential of STING activation in various malignancies. -
STING Agonist
STING agonist-48 is a selective agonist that activates the Stimulator of Interferon Genes (STING) pathway, demonstrating an EC50 value of 4.02 μM in vitro. It preferentially binds to the transmembrane domain, influencing downstream immune responses. This compound enhances immunogenicity by promoting IgG and Th1/Th2 cytokine responses in humanized STING mice, making it a valuable tool for investigating inflammation-related diseases and potential adjuvant therapies. -
STING Agonist
STING agonist-21 is a potent STING agonist that demonstrates an EC50 of 592.8 nM. It is designed to activate the stimulator of interferon genes (STING) pathway, which plays a crucial role in immune response modulation. This compound is primarily utilized in cancer research to investigate its effects on tumor immunity and potential therapeutic applications in oncological therapies. -
STING Agonist
Ulevostinag (isomer 2) is a selective STING (Stimulator of Interferon Genes) agonist. It activates the STING pathway, leading to enhanced production of type I interferons and pro-inflammatory cytokines. This compound is primarily utilized in research focused on cancer immunotherapy, infectious diseases, and autoimmune disorders to investigate the therapeutic potential of STING activation in modulating immune responses. -
STING Agonist
STING agonist-38 is a potent agonist of the stimulator of interferon genes (STING), demonstrating an EC50 of 0.05 μM in THP1 cells. This compound exhibits notable oral bioactivity and can effectively activate STING-mediated immune responses. It is valuable for research in immuno-oncology and pathogen response studies. -
STING Modulator
STING modulator-7 is a potent modulator of the stimulator of interferon genes (STING), enhancing the signaling pathway associated with innate immune responses. This compound exhibits significant biological activity in activating STING-dependent pathways, promoting type I interferon production and immune cell activation. It is primarily utilized in research applications focused on cancer immunotherapy, infectious disease models, and studies of immune system regulation. -
STING Agonist
Ulevostinag (isomer 3) is a potent STING (Stimulator of Interferon Genes) agonist that functions through the activation of the STING pathway, leading to the induction of type I interferons and other cytokines. This compound has demonstrated significant biological activity in promoting anti-tumor immune responses, making it an essential tool for cancer immunotherapy research. Its ability to modulate immune signaling pathways positions Ulevostinag (isomer 3) as a valuable reagent in the study of immune activation and anti-cancer strategies. -
STING Agonist
Ulevostinag (isomer 4) is a potent STING (Stimulator of Interferon Genes) agonist that activates the STING signaling pathway, leading to the production of type I interferons and other pro-inflammatory cytokines. This compound enhances the immune response, making it valuable for research in cancer immunotherapy and infectious disease. Ulevostinag (isomer 4) serves as an important tool for studying STING-mediated pathways and their role in immune modulation. -
TpoR Agonist
Totrombopag is an orally active thrombopoietin receptor (TpoR) agonist. It activates TpoR, triggering an intracellular signaling cascade involving JAK2 kinase and the transcription factor Stat5, which is crucial for the regulation of megakaryocyte growth and differentiation into platelets. This compound is valuable for research into platelet production and the biology of megakaryocytes. -
TpoR Agonist
Totrombopag choline is a potent thrombopoietin receptor (TpoR) agonist that effectively stimulates megakaryocyte growth and platelet production. By activating TpoR, it triggers a signaling cascade involving JAK2 kinase and Stat5, which plays a crucial role in megakaryocyte differentiation. This compound is valuable for research focused on platelet biology and the mechanisms regulating thrombopoiesis. -
TLR7 Agonist
SMU-L11 is a selective TLR7 agonist with an EC50 of 0.024 μM, which engages the MyD88 adapter protein to activate downstream NF-κB and MAPK signaling pathways. This compound significantly enhances immune cell activation in murine models, promoting the proliferation of CD4+ T and CD8+ T cells, leading to direct tumor cell lysis and inhibition of tumor growth. SMU-L11 is a valuable reagent for cancer research and can also be utilized for investigations into immune system-related diseases. -
TLR4/HCN Inhibitor
HCN-IN-1 is a TLR4 inhibitor and modulator of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, specifically targeting HCN2 and HCN4. It effectively inhibits TLR4-mediated signaling, evidenced by reduced alkaline phosphatase activity. HCN-IN-1 modulates HCN2 currents by shifting the voltage-dependent activation to hyperpolarized potentials and slowing activation kinetics, while also blocking currents through HCN4 channels. This compound demonstrates significant analgesic, anti-inflammatory, and anti-anginal properties, making it valuable for research into inflammatory pain, neuropathic pain, heart failure, and related inflammatory conditions. -
Anti-CD33 Antibidy
Vadastuximab is a humanized monoclonal antibody that selectively targets CD33, a cell surface protein predominantly expressed on myeloid cells and acute myeloid leukemia (AML) cells. This antibody is instrumental in the development of antibody-drug conjugates (ADCs) designed for targeted therapeutic applications. Research indicates that Vadastuximab can enhance the efficacy of cancer treatments by delivering cytotoxic agents directly to CD33-expressing tumors, thereby promoting precise tumor eradication while minimizing off-target effects. -
CD33 Splicing Modulator
CD33 Splicing Modulator 1 is an innovative agent that targets the CD33/Siglec 3 receptor, a crucial regulator of microglial activity in the myeloid lineage. This compound enhances exon 2 skipping in cellular mRNA, thereby altering CD33 expression. It holds promise as a research tool in neurodegenerative disease studies, particularly in the context of Alzheimer's disease, facilitating a deeper understanding of the underlying mechanisms of these conditions. -
FKBPL Peptide
AD 01 is a 24-amino acid peptide derived from FKBPL (FK506-binding protein like), targeting the CD44 receptor to exert significant anti-angiogenic effects. By binding to CD44, AD 01 effectively inhibits tumor cell migration in a manner dependent on this receptor. This peptide is valuable for research applications focused on cancer biology, particularly in studies related to angiogenesis and tumor metastasis. -
MR1 Antigen
Photolumazine III is an MR1 (MHC class I-related molecule 1) antigen, which plays a crucial role in the immune response by presenting antigenic metabolites to T cells. This compound exhibits biological activity related to the activation of MR1-restricted T cell responses, thus serving as a valuable tool for studying immune mechanisms and developing immunotherapies. Research applications include the investigation of microbial and tumor-associated antigens, as well as the modulation of immune responses in various disease models. -
Anti-EpCAM/TROP1/CD326 Antibody
Varsetatug is a humanized IgG1κ monoclonal antibody that targets the epithelial cell adhesion molecule (EpCAM), also known as TROP1 or CD326. This antibody exhibits significant antitumor activity, making it a valuable tool for studying various malignancies, including breast, prostate, and ovarian cancers. Varsetatug is instrumental in cancer research, particularly in investigating therapeutic approaches that exploit EpCAM pathways. -
CD8 T Cell Epitope
TYVPANASL is a MHC I-binding CD8 T cell epitope derived from the HER2/neu protein. This nine-amino-acid peptide plays a crucial role in stimulating CD8 T cell responses, making it valuable in immunological studies and vaccine development. TYVPANASL can be utilized in the preparation of J-LEAPS vaccines, contributing to cancer immunotherapy research. -
CD36 Ligand
KDdiA-PC is a highly potent ligand for CD36, primarily targeting the receptor that mediates the cellular response to oxidized low-density lipoprotein (oxLDL). Its significant biological activity facilitates studies on lipid metabolism, inflammation, and atherosclerosis. KDdiA-PC is valuable for researchers investigating the role of CD36 in various physiological and pathological processes. -
CD63-binding Peptide
CP05 is a CD63-binding peptide that specifically interacts with the exosome surface marker CD63. This interaction facilitates the anchoring of exosomes to target tissues, enhancing in vivo delivery of exosomal payloads. CP05 is useful in research applications focused on drug delivery, therapeutic targeting, and the study of exosome biology. -
CD36 Peptide
CD36 Peptide P (139-155), Cys conjugated targets the CD36 protein and serves as a crucial tool for studying its function. This Cys-conjugated peptide is effective in inhibiting the immunoadsorption of CD36 by the OKM5 antibody, making it valuable for research applications focused on immune responses and metabolic processes. The peptide can aid in the investigation of CD36-related pathways and its role in various biological contexts. -
Anti-PD-1/TIGIT Antibody
Nilvanstomig is an anti-PD-1/TIGIT antibody that targets the PD-1/TIGIT pathway, thereby facilitating T cell activation and enhancing natural killer (NK) cell anti-tumor activity. This compound is particularly relevant in the study of advanced cervical cancer and contributes to research focused on immune modulation and cancer immunotherapy. Its mechanism of action underscores its potential for strengthening anti-tumor responses in various oncological contexts. -
CD36 Peptide
CD36 Peptide P (93-110), Cys conjugated specifically targets CD36, a multifunctional receptor involved in cellular adhesion and lipid metabolism. This peptide has been shown to block the binding of CD36 to immobilized thrombospondin, thereby providing valuable insights into CD36-mediated pathways. Additionally, it partially inhibits collagen-induced platelet aggregation, making it useful for research applications related to cardiovascular function and cell signaling. -
Anti-CD326/EPCAM Antibody
Anti-CD326/EPCAM Antibody (3622W94) is a humanized antibody that specifically targets the epithelial cell adhesion molecule (EpCAM/CD326), a key player in cell-cell adhesion and signaling. This antibody is suitable for research applications focused on various epithelial cancers, including pancreatic, prostate, and breast cancer. Its ability to interfere with tumor progression and metastasis makes it a valuable tool for studies in cancer biology and therapeutic development. -
Anti-CEACAM5/CEA/CD66e Antibody
Altumomab is a human monoclonal antibody that selectively targets CEACAM5 (carcinoembryonic antigen, CEA) and CD66e. This antibody is primarily utilized in cancer research, particularly for tumor identification and immunotherapy applications. Its specificity for CEACAM5 makes it a valuable tool in the study of various malignancies, enabling enhanced detection and therapeutic strategies against CEA-expressing tumors. -
CD33 Splicing Modulator
CD33 splicing modulator 1 hydrochloride is a small molecule modulator that targets CD33/Siglec 3, a myeloid cell surface receptor that regulates microglial activity. This compound promotes exon 2 skipping in cellular mRNA, making it a valuable tool for investigating the molecular mechanisms underlying neurodegenerative diseases, particularly Alzheimer's disease. It provides researchers with a means to explore potential therapeutic approaches through modulation of splicing events related to CD33.
